E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Extensive-Stage Small Cell Lung Cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer of small lung cells |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041068 |
E.1.2 | Term | Small cell lung cancer extensive stage |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Assess the dose -limiting toxicities (DLTs) and define the Phase 2 dose of G1T28 administered with topotecan (please note this is related only to Part 1 - Phase 1b study; we will be conducting only Part 2- Phase 2a study) 2. Assess the safety and tolerability of G1T28 administered with topotecan |
|
E.2.2 | Secondary objectives of the trial |
1. Assess the pharmacokinetic (PK) profile of G1T28 2. Assess the PK profile of topotecan when administered with G1T28 3. Assess the hematologic profile (kinetics and incidence/duration/frequency of toxicities) of G1T28 administered with topotecan 4. Assess the incidence of febrile neutropenia 5. Assess the incidence of infections 6. Assess the utilization of red blood cells (RBC) and platelet transfusions 7. Assess the utilization of hematopoietic growth factors 8. Assess the utilization of systemic antibiotics 9. Assess the incidence of chemotherapy dose reductions and dose interruptions overall 10. Assess the incidence of Grade 2 or greater nephrotoxicity 11. Assess tumor response based on RECIST, Version 1.1 12. Assess progression free survival (PFS) and overall survival |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years 2. Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry 3. Progression during or after prior first- or second-line chemotherapy and eligible to receive topotecan therapy 4. At least 1 target lesion that is measurable by RECIST, Version 1.1 5. Absolute neutrophil count ≥ 1.5 × 109/L 6. Platelet count ≥ 100 × 109/L 7. Creatinine ≤ 1.5 mg/dL and creatinine clearance (CrCl) of ≥ 60 mL/minute) 8. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) 9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; ≤ 5 × ULN in the presence of liver metastases 10. Serum albumin ≥ 3 g/dL 11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 12. All clinically significant toxicities from previous anticancer therapy must have resolved to ≤ Grade 1 (except for hemoglobin) 13. Contraception: a. For females: All females of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-hCG) test result at screening and negative serum or urine β-hCG test result at baseline. Females must be either postmenopausal, surgically sterile, or using an acceptable method of contraception. Acceptable surgical sterilization techniques are hysterectomy, bilateral tubal ligation with surgery at least 6 months prior to dosing, and bilateral oophorectomy, with surgery at least 2 months prior to dosing. Acceptable methods of contraception are an intrauterine device, contraceptive implant, oral contraceptive (stable dose of the same hormonal contraceptive product for at least 3 months prior to dosing), a vasectomized partner, and a barrier method (condom or diaphragm) during the study and for 3 months after discontinuation of treatment b. For males: Patients with female partner of childbearing potential must agree to use a highly effective form of birth control, which entails the use of oral, injected, or implanted hormonal methods of contraception or an intrauterine device/system by the female partner, in combination with a barrier method (eg, condom, diaphragm, cervical cap) during the study and for 3 months after discontinuation of treatment, and will also refrain from sperm donation for 3 months following completion of the study 14. Able to understand and sign an informed consent |
|
E.4 | Principal exclusion criteria |
1. History of topotecan treatment for SCLC 2. Presence of brain metastases requiring immediate treatment with radiation therapy or steroids 3. History of other malignancies, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for ≥ 3 years 4. Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association [NYHA] functional classification system) 5. Known history of stroke or cerebrovascular accident within 6 months prior to enrollment 6. Serious active infection 7. Psychiatric illness/social situations that would limit study compliance 8. Other uncontrolled serious chronic disease or conditions that in the investigator’s opinion could affect compliance or follow-up in the protocol 9. History of upper gastrointestinal bleeding, ulceration, perforation, or significant gastrointestinal disease within 12 months prior to study enrollment 10. Known human immunodeficiency virus (HIV) positive; known hepatitis B virus (HBV) positive; or known hepatitis C virus (HCV) positive that is symptomatic or requiring active therapy 11. Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) 12. Receipt of any systemic chemotherapy regimen within 4 weeks prior to enrollment or a noncytotoxic investigational medication within 2 weeks prior to enrollment 13. Hypersensitivity to any of the components of the formulation of topotecan 14. Legal incapacity or limited legal capacity 15. Pregnant or lactating women |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the safety and tolerability of combining G1T28 with topotecan and to evaluate the effect of G1T28) on chemotherapy induced myelosuppression.
(NOTE: relevant for Part 2 - Phase 2a study) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• To assess the pharmacokinetic (PK) profile of G1T28 • To assess the hematologic profile (kinetics and incidence/duration/frequency of toxicities) of G1T28 administered with topotecan • To assess the incidence of febrile neutropenia • To assess the incidence of infections • To assess the utilization of Red Blood Cells (RBC) and platelet transfusions • To assess the utilization of hematopoietic growth factors • To assess the utilization of systemic antibiotics • To assess the incidence of chemotherapy dose reductions and dose interruptions overall • To assess the incidence of Grade 2 or greater nephrotoxicity • To assess tumor response based on RECIST,Version 1.1 • To assess progession-free survival (PFS) and overall survival
(NOTE: relevant for Part 2 - Phase 2a study) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bosnia and Herzegovina |
Macedonia, the former Yugoslav Republic of |
Serbia |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patients will be followed for survival via monthly phone calls at a minimum until 50% of the patients in Part 2 of the study have died. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |